summary: The IFN-beta represents one of the most widely used treatments in MS. Nevertheless, its efficacy might be diminished by the presence of neutralising antibodies (NAbs), which reflect an immune reaction against the treatment. In this multicentre study the authors looked at the harmful effects produced by NAbs on clinical and MRI outcomes produced by NAbs. They found that even though MRI parameters showed worse evolution in people with higher NAbs frequency, no effect of NAbs on clinical outcome was observed.

authors: Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M

source: Expert Opin Biol Ther. 2009 Mar 11

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: